Interactome Bio’s Press Releases

Interactome Bio is advancing the science, medicine and enterprise of biotechnology. Stay up to date with the latest news and our business development updates.

Thanks for joining our newsletter.
Oops! Something went wrong.
Interactome Biotherapeutics Announces Exclusive Global Option Agreement & Partnership with Oxford University Innovation
Calendar Icon - Technology Webflow Template
March 25, 2025
Clock Icon - Technology Webflow Template
min read

Interactome Biotherapeutics Announces Exclusive Global Option Agreement & Partnership with Oxford University Innovation

Partnership to accelerate development of Novel Small Extracellular Vesicle CNS Drug Delivery Platform

James T. Secrest, MS, DC
James T. Secrest, MS, DC
Director, Research and Development
Press Release
Interactome Biotherapeutics Accepted into MassBio Drive Spring Cohort
Calendar Icon - Technology Webflow Template
March 18, 2025
Clock Icon - Technology Webflow Template
3
min read

Interactome Biotherapeutics Accepted into MassBio Drive Spring Cohort

Interactome Biotherapeutics Accepted into MassBio Drive Spring Cohort

James T. Secrest, MS, DC
James T. Secrest, MS, DC
Director, Research and Development
Press Release
Interactome Biotherapeutics Forms Scientific Advisory Board for Development of Nerve Injury-Focused EV Therapeutic IB001
Calendar Icon - Technology Webflow Template
December 10, 2024
Clock Icon - Technology Webflow Template
6
min read

Interactome Biotherapeutics Forms Scientific Advisory Board for Development of Nerve Injury-Focused EV Therapeutic IB001

Interactome Biotherapeutics, announces the appointment of a distinguished group of experts to its Board

James T. Secrest, MS, DC
James T. Secrest, MS, DC
Director, Research and Development
Press Release
Interactome Biotherapeutics enters Exclusive License Agreement with Henry Ford Health to Advance sEV-Based Therapies
Calendar Icon - Technology Webflow Template
October 16, 2024
Clock Icon - Technology Webflow Template
8
min read

Interactome Biotherapeutics enters Exclusive License Agreement with Henry Ford Health to Advance sEV-Based Therapies

Interactome Biotherapeutics enters Exclusive License Agreement with Henry Ford Health

James T. Secrest, MS, DC
James T. Secrest, MS, DC
Director, Research and Development
Press Release
Email Icon - Technology Webflow Template

Subscribe to receive articles directly in your inbox

Thanks for joining our newsletter.
Oops! Something went wrong.